MedTrace Logo

FHD-286 in Subjects With Metastatic Uveal Melanoma

NCT04879017 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2024-04-25

No results posted yet for this study

Summary

This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 oral monotherapy in subjects with metastatic Uveal Melanoma (UM).

Conditions

  • Metastatic Uveal Melanoma

Interventions

DRUG

FHD-286

FHD-286 as a single agent

Sponsors & Collaborators

  • Foghorn Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Sarah Reilly, MD · Foghorn Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-11
Primary Completion
2023-11-30
Completion
2023-11-30
FDA Drug
Yes

Countries

  • United States
  • France
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04879017 on ClinicalTrials.gov